Investors & Media

Press Releases

Press Releases

Date Title View
May 3, 2023 Sage Therapeutics to Present at Upcoming May Investor Conferences
May 2, 2023 Sage Therapeutics Announces First Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
April 18, 2023 Sage Therapeutics to Report First Quarter 2023 Financial Results on Tuesday, May 2, 2023
March 22, 2023 Sage Therapeutics to Present at the Stifel 2023 CNS Days
March 16, 2023 Sage Therapeutics Appoints Jessica Federer to Board of Directors
March 8, 2023 Sage Therapeutics and Biogen Share Update on FDA Advisory Committee for Zuranolone
February 28, 2023 Sage Therapeutics to Present at the Cowen 43rd Annual Health Care Conference
February 22, 2023 Sage Therapeutics Announces European Medicines Agency Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntington’s Disease
February 16, 2023 Sage Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Highlights Pipeline and Business Progress
February 6, 2023 Sage Therapeutics and Biogen Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
Displaying 11 - 20 of 23